Welcome to our dedicated page for KONINKLIJKE PHILIPS NV SEC filings (Ticker: RYLPF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on KONINKLIJKE PHILIPS NV's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into KONINKLIJKE PHILIPS NV's regulatory disclosures and financial reporting.
Koninklijke Philips N.V. reported Q3 2025 results showing continued momentum: comparable order intake grew 8% and group sales were EUR 4.3 billion, up 3.3% on a comparable basis. Income from operations was EUR 330 million. The adjusted EBITA margin rose 50 bps to 12.3% as higher sales, mix and productivity more than offset tariff headwinds.
Operating cash flow was EUR 327 million with free cash flow of EUR 172 million. Segment trends were mixed: Diagnosis & Treatment comparable sales grew 1.3% with margin at 11.8% (down 80 bps), Connected Care grew 5.1% with margin up 410 bps to 11.4%, and Personal Health grew 10.9% with margin at 17.1%.
Philips reiterated its full‑year 2025 outlook: comparable sales growth of 1%–3%, adjusted EBITA margin of 11.3%–11.8% now expected toward the upper end, and free cash flow of EUR 0.2–0.4 billion, which includes the EUR 1,025 million settlements paid in Q1 2025. The outlook excludes ongoing Philips Respironics‑related proceedings.